Valor202320242025TTMGastos comerciales, generales y administrativos6.14 B6.33 B6.09 B6.09 BInvestigación y desarrollo399 M408 M382 M382 MBeneficio operativo2.51 B1.84 B2.41 B2.41 BTotal de ingresos no operativos-72 M-48 M-36 M-36 MGastos por intereses, netos de intereses capitalizados250 M431 M430 M430 MIngresos no operativos, una vez deducidos los gastos por intereses-308 M-483 M-476 M-476 MIngresos/gastos extraordinarios-14 M4 M10 M10 MBeneficio antes de impuestos2.19 B1.42 B2 B2 BParticipación en los beneficios————Impuestos526 M385 M529 M529 MParticipación minoritaria————Otros ingresos/gastos después de impuestos-6 M-69 M-67 M-67 MBeneficio neto antes de actividades interrumpidas1.66 B1.03 B1.47 B1.47 BOperaciones suspendidas————Beneficio neto1.66 B1.03 B1.47 B1.47 BAjuste por dilución————Dividendos de las acciones preferentes————Beneficio neto diluido atribuible a los accionistas1.66 B1.03 B1.47 B1.47 BBeneficio básico por acción0.90.540.770.77Beneficio por acción diluido0.90.540.760.76Número medio de acciones ordinarias1.85 B1.92 B1.92 B7.67 BAcciones diluidas1.85 B1.92 B1.92 B7.7 BEBITDA1.83 B1.48 B1.98 B1.58 BEBIT1.2 B860 M1.42 B1.03 BCosto de los ingresos6.8 B6.5 B6.33 B6.33 BOtros costes de producción————Amortización y depreciación (flujo de caja)627 M622 M557 M557 M
Kenvue Inc
Kenvue Inc. is an American consumer health company. Formerly the Consumer Healthcare division of Johnson & Johnson, Kenvue owns well-known brands such as Aveeno, Band-Aid, Benadryl, Combantrin, Zyrtec, Johnson's, Listerine, Lactaid, Mylanta, Neutrogena, Trosyd, Calpol, Tylenol, and Visine. Kenvue is incorporated in Delaware and was originally headquartered in the Skillman section of Montgomery Township, New Jersey, before relocating to Summit, New Jersey.
Johnson & Johnson announced in November 2021 that it would spin off its consumer health division as a separate company. The new company was named Kenvue in September 2022, and its initial public offering took place in May 2023, raising $3.8 billion in the largest U.S. IPO since 2021, with an initial valuation of about $41 billion. Johnson & Johnson initially retained more than 90% ownership before completing a full separation through a share exchange in July 2023. Kenvue was subsequently added to the S&P 500 Dividend Aristocrats index.
CEO Thibaut Mongon initially led Kenvue, which employed about 22,200 people in 2022. Following Mongon’s termination in 2025, Kirk Perry was named interim CEO.